ATHX · Athersys, Inc / New - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.0K | $49.0K | $0 | - | $65.0K | $2.32M | $2.91M | - | $4.79M | $0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $4.00M | $10.65M | $4.47M | - | $12.42M | $20.79M | $20.94M | - | $17.16M | $17.69M |
| SG&A | $2.81M | $2.35M | $2.81M | - | $3.74M | $5.16M | $4.10M | - | $3.63M | $4.16M |
| Total Operating Expenses | $7.78M | $13.04M | $7.33M | - | $16.78M | $26.57M | $25.29M | - | $21.01M | $18.42M |
| D&A | $977.0K | $43.0K | $52.0K | - | $617.0K | $618.0K | $247.0K | - | $220.0K | $723.0K |
| Operating Income | ($7.78M) | ($12.99M) | ($7.33M) | - | ($16.71M) | ($24.26M) | ($22.38M) | - | ($16.22M) | ($22.57M) |
| Interest Expense | $211.0K | $6.0K | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($3.77M) | ($12.92M) | ($7.81M) | - | ($13.67M) | - | ($22.22M) | - | - | - |
| EPS - Basic | ($0.15) | ($0.62) | ($0.43) | - | ($1.15) | ($90.00) | ($0.09) | - | ($0.07) | ($0.10) |
| EPS - Diluted | - | ($0.62) | ($0.43) | - | ($1.15) | ($90.00) | ($0.09) | - | ($0.07) | ($0.10) |
Balance Sheet
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.02M | $1.80M | $3.12M | $9.04M | $13.78M | $13.38M | $21.80M | $37.41M | $49.67M | $56.65M |
| Accounts Receivable | - | - | - | $716.0K | - | $600.0K | - | $1.41M | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $9.29M | $8.70M | $28.96M | $27.77M | - | - | - | $15.78M | - | - |
| Current Assets | $2.23M | $3.69M | $7.84M | $13.54M | $20.75M | $21.38M | $31.10M | $46.03M | $58.14M | $59.44M |
| Total Assets | $7.43M | $10.48M | $21.63M | $27.73M | $35.54M | $35.20M | $44.96M | $60.18M | $72.09M | $73.30M |
| Current Liabilities | $38.62M | $42.70M | $39.68M | $38.44M | $38.73M | $33.22M | $30.96M | $29.86M | $27.68M | $28.30M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | ($36.40M) | ($37.42M) | ($31.01M) | ($23.85M) | ($16.61M) | ($11.74M) | $307.0K | $16.37M | $29.35M | $31.05M |
| Retained Earnings | ($680.38M) | ($676.61M) | ($663.69M) | ($655.88M) | ($642.88M) | ($629.21M) | ($605.56M) | ($583.34M) | ($561.63M) | ($545.46M) |
Cash Flow
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($5.97M) | - | - | - | ($20.17M) | - | - | - |
| Investing Cash Flow | - | - | $105.0K | - | - | - | ($186.0K) | - | - | - |
| Financing Cash Flow | - | - | ($56.0K) | - | - | - | $4.74M | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -11969.2% | -26506.1% | - | - | -25712.3% | -1047.4% | -768.5% | - | -338.5% | - |
| EBITDA margin | -10466.2% | -26418.4% | - | - | -24763.1% | -1020.7% | -760.0% | - | -333.9% | - |
| Net margin | -5801.5% | -26375.5% | - | - | -21029.2% | - | -762.9% | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | 6146.2% | 21732.7% | - | - | 19113.8% | 897.8% | 719.2% | - | 358.1% | - |
| SG&A / Revenue | 4320.0% | 4785.7% | - | - | 5749.2% | 222.9% | 140.8% | - | 75.8% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -50.8% | -123.4% | -36.1% | - | -38.5% | - | -49.4% | - | - | - |
| Return on equity | 10.4% | 34.5% | 25.2% | - | 82.3% | - | -7236.5% | - | - | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.06 | 0.09 | 0.20 | 0.35 | 0.54 | 0.64 | 1.00 | 1.54 | 2.10 | 2.10 |
| Quick ratio | 0.06 | 0.09 | 0.20 | 0.35 | 0.54 | 0.64 | 1.00 | 1.54 | 2.10 | 2.10 |
| Cash ratio | 0.03 | 0.04 | 0.08 | 0.24 | 0.36 | 0.40 | 0.70 | 1.25 | 1.79 | 2.00 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -36.9x | -2164.7x | - | - | - | - | - | - | - | - |
| Equity multiplier | -0.20 | -0.28 | -0.70 | -1.16 | -2.14 | -3.00 | 146.45 | 3.68 | 2.46 | 2.36 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.01 | 0.00 | 0.00 | - | 0.00 | 0.07 | 0.06 | - | 0.07 | 0.00 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | 95d | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 0.0% | -97.9% | -100.0% | - | -98.6% | - | - | - | 5472.1% | -100.0% |
| Revenue CAGR (3y) | -8.9% | -16.4% | - | - | - | -18.4% | 26.3% | - | 129.0% | - |
| Revenue CAGR (5y) | -30.4% | -40.7% | - | - | -30.4% | 28.2% | 14.7% | - | 72.8% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 53.4% | 46.5% | 67.2% | - | -3.0% | -7.5% | 15.8% | - | 27.3% | -23.1% |
| Net income growth (YoY) | 72.4% | - | 64.8% | - | - | - | 16.1% | - | - | - |
| EPS growth (YoY) | - | 99.3% | -377.8% | - | -1542.9% | -89900.0% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -119.1% | -218.8% | - | - | - | - | -99.2% | -47.8% | -33.5% | -51.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$5.51M totalService$5.23M · 94.9%
Product$283.0K · 5.1%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ATHERSYS against the 5 most active filers in the same SIC group.